Veralox Therapeutics is a startup currently headquartered at the Frederick Innovation Technology Center, Inc. (FITCI) in Frederick, Maryland. As a small molecule therapeutics company focused on developing medicines targeting the arachidonic acid pathway, they have two drug products in development for the treatment of a rare blood disorder known as heparin-induced thrombocytopenia and thrombosis and Type 1 Diabetes.
The BioBuzz team recently caught up with Veraloxs CEO Dr. Jeff Strovel, who spoke about the genesis of Veralox, its advancing pipeline, the companys recent milestones and its outlook for the future.
Tell our audience a bit about the founding of Veralox Therapeutics
Ill never forget the day a trusted colleague, David Maloney, called me when I was driving back to my office. He told me he had been working to develop a clinical candidate that selectively targeted the arachidonic acid (AA) pathway through inhibition of a protein called 12-Lipoxygenase. He believed the program was ready to be brought into a company, and there was potential for broad therapeutic utility of the inhibitor, which was intriguing. I have heard a lot of drug program pitches and usually get a sense of where the holes are pretty quickly. In this case, we talked for 30 minutes and afterward I knew this program was ready for company formation. Our first product in development, VLX-1005, is for treatment of the rare blood disorder heparin-induced thrombocytopenia & thrombosis (HITT) which also happens to be the same blood disorder that nearly killed my father years ago. We started the company in 2017 along with Daves colleague from the NCATS (National Center for Advancing Translational Sciences) at the NIH, Matt Boxer, with our rare disease blood disorder drug as our lead candidate. I feel the stars really aligned for us and we have been charging ahead ever since.
Dave, in collaboration with several other partners, led the development of our lead candidate, VLX-1005 while he was a chemistry Group Leader at NCATS.
What is your life science background and what did you do prior to co-founding Veralox?
I hold a Ph.D. in Human Genetics from the University of Maryland School of Medicine. I then went on to be a clinical cytogenetics fellow at the National Cancer Institute Department of Pathology at the NIH. While at NIH I developed a drug target ID platform that got the interest of companies doing cancer drug discovery and I eventually joined a company called Avalon, where I worked in drug discovery and development for about 9 years and served my last two years as Head of Translational Oncology. I learned a great deal about the drug discovery and development process during my time there.
After Avalon I was part of a group of local life science veterans that co-founded the Clinical Research Organization (CRO) Noble Life Sciences. The CRO also served as a kind of incubator for new companies. We incubated several new companies like Neximmune and Convergene Pharmaceuticals, where I served as Chief Scientific Officer and President from 2011 to 2015 before taking on the Chief Executive role from 2015 to 2017. During that time I had met and worked with Dave and I left Convergene to start Veralox with him and our other co-founder Matthew Boxer.
What is Veraloxs lead drug candidate, what disease does it target and where does it sit in the development process?
Our lead drug candidate is for the treatment of patients with HITT, which is a rare, life-threatening disease caused by an immune reaction to Heparin. This drug candidate is a small molecule product that inhibits the 12-lipoxygenase (12-LOX) enzyme which produces 12-HETE. Both 12-LOX and 12-HETE are implicated in numerous diseases. The only FDA-approved drug for HIT/HITT, argatroban, doesnt treat the underlying cause of the disease and has significant potential side effects leaving a significant unmet need.
There are approximately 50,000 people that will be diagnosed with HIT/HITT in the US this year but the number of those treated for this disease is approximately 150,000 annually. HIT takes time to diagnose and doctors cant wait for a definitive diagnosis to make treatment decisions. If patients are suspected of having the disease they must be treated immediately given the risk for deadly thrombosis. The current approved treatment, argatroban, can cause major bleeds which in and of itself can lead to death in these patients. Better drugs are needed that address the pathology of the disease without contributing potentially lethal side effects.
Our HIT treatment inhibits the underlying pathophysiology of HITT to halt the aberrant immune response driving the disease and essentially offering the potential of a curative modality.
Weve been strategically focused on HIT/HITT, but our approach has potential for a number of other indications. For our HIT/HITT drug candidate, weve submitted our Orphan Drug application and our pre-IND (Investigational New Drug) briefing book to the FDA; we expect to have our GMP material soon and to start GLP toxicology studies in the second quarter of this year. Our team expects to submit the IND for our lead candidate by the end of 2020. We are also co-developing a small molecule, orally administered drug product. We plan to advance this candidate for the treatment for Type 1 Diabetes, which is about a year behind our HIT/HITT clinical candidate.
What are some recent Veralox funding milestones and what are the companys next funding steps?
Weve had success raising capital from grants and venture capital groups. Veralox received about 300K from NIHs Small Business Innovation Research (SBIR) Fund, Phase I, and $300K from NIHs Small Business Technology Transfer (STTR) Fund. We also recently closed a $5.4M seed round that was co-led by Sanofi Ventures and the JDRF T1D Fund and included participation from the VTC Innovation and VTC Seed Fund, the Maryland Momentum Fund, the University of Vermont Health Network and TEDCO.
We are currently raising Series A funding to support clinical development of VLX-1005 for HITT and advance our second drug product for treatment of Type 1 Diabetes into clinical trials. Weve initiated discussions with several large venture capital firms all of which could lead our funding round and have the full support of our current investors in the process.
What can you tell us about your experience at FITCI and as a startup in the Frederick life science ecosystem?
Ive had experiences with other incubators, some of which no longer exist, but theres no comparison to FITCI. They offer great support to emerging companies that desperately need it at the early stages. I have been at other incubators that give you a physical place to do business, but FITCI really keeps an eye on you. The FITCI team helps you solve problems and they offer quarterly meetings for the CEOs to meet with groups of successful business people who can offer advice and provide mentorship for those in need. These mentors might not be in therapeutics but theyve done this before and can really help.
I really love Frederick because, to me, the area is just like a startup. Its really going somewhere. FITCI has two locations, but whenever we meet with people, we use the Market Street location in downtown Frederick. Its a nice face to show off to people from outside of the area. Our time at FITCI is nearing its end because of our funding success, but when we graduate from the incubator, the plan is to stay in Frederick. Weve already been looking at a few places.
What are some near term challenges for Veralox and where do you see the company being in three to five years?
Our biggest challenge is developing a completely novel first-in-class product. Theres no blueprint or recipe one can exactly follow, and it is challenging. This is, however, what the Veralox team is trained to do and we are well prepared and excited by the challenge and promise of developing a new treatment that can drastically improve and perhaps save the lives of people suffering from a terrible disease.
Were also currently looking to hire a Chief Medical Officer soon. Finding the best talent is always a challenge, but I know well be able to find the right person.
In three to five years, our goal is to have several products in the clinic and possibly an approved HIT/HITT drug on the market. Veralox has the potential to become an anchor life science company in the region. But for now, Id like Veralox to be known as the company that did what they said theyd do were community-minded and will continue to work hard to make a difference in the lives of patients with debilitating diseases.
Steve has over 20 years experience in copywriting, developing brand messaging and creating marketing strategies across a wide range of industries, including the biopharmaceutical, senior living, commercial real estate, IT and renewable energy sectors, among others. He is currently the Principal/Owner of StoryCore, a Frederick, Maryland-based content creation and execution consultancy focused on telling the unique stories of Maryland organizations.
See the original post here:
- Human genetics - Wikipedia - June 22nd, 2020
- human genetics | Description, Chromosomes, & Inheritance ... - June 22nd, 2020
- Human Genetics - David Geffen School of Medicine at UCLA - June 22nd, 2020
- Genetic Mutations as a Tool To Predict Lifespan and Fertility - Technology Networks - June 22nd, 2020
- Human Genetics Market Analysis with Key Players, Applications, Trends and Forecasts to 2026 - Farmers Ledger - June 22nd, 2020
- China Is Collecting DNA From Tens of Millions of Men and Boys, Using U.S. Equipment - The New York Times - June 22nd, 2020
- Researchers identify environmental components that affect gene expression in cardiovascular disease - The South End - June 22nd, 2020
- China collects DNA from millions of men and boys - BioNews - June 22nd, 2020
- Exposure and engagement with tobacco-related social media and associations with subsequent tobacco use among young adults: A longitudinal analysis. -... - June 22nd, 2020
- COVID-19 Test Samples: Why Do We Swab Instead of Spit? - The Wire - June 22nd, 2020
- Coronavirus news and updates: Does Florida's spike in cases make it a new 'epicenter'?; mask rules on airplanes from the FAA - USA TODAY - June 22nd, 2020
- The beauty of flaws - NCC Linked - June 22nd, 2020
- Study finds genetic factors that make some more susceptible to Covid-19 - Health24 - June 22nd, 2020
- Assessment of COVID-19's Effect on Precision Medicine Software Market 2020-2024 | Benefits of Precision Medicine to Augment Growth | Technavio -... - June 22nd, 2020
- Wellness Experts Discuss The Importance Of Individualizing Your Approach To Health - Forbes - June 22nd, 2020
- 1.4 million for genetics research on how obesity in pregnancy affects mother and baby - Mirage News - June 9th, 2020
- Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma - GlobeNewswire - June 9th, 2020
- Amgen To Present At The Goldman Sachs 41st Annual Global Healthcare Conference - Monterey County Weekly - June 9th, 2020
- COVID-19 Pandemic: Global Risks of More Complex Character and the Visions of the Future World - Valdai Discussion Club - May 19th, 2020
- Rothamsted turn to harvesting coronavirus data - Lab News - May 19th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - UAB News - May 19th, 2020
- DU to set up School of Public Health - The Indian Express - May 19th, 2020
- Covid-19 research: 45 Bengaluru startups working on medicine, testing methods and vaccine - Economic Times - May 19th, 2020
- Immortalized Cell Line Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty - May 19th, 2020
- Worlds Shortest Population Reveal the Largest Genetic Contributor to Height - Technology Networks - May 15th, 2020
- Group of Genes Have Altered Expression in Autism - Technology Networks - May 15th, 2020
- Why can two young and healthy individuals be affected so differently by coronavirus? - Health24 - May 15th, 2020
- Amgen To Present At The Bank Of America Merrill Lynch Virtual Global Healthcare Conference - BioSpace - May 15th, 2020
- Viewpoint: Darwin's 'Descent of Man' is both deeply disturbing and more relevant than ever - Genetic Literacy Project - May 15th, 2020
- Study Finds Low Proportion of Individuals With Autism Receive Recommended Genetic Tests - Technology Networks - May 15th, 2020
- Cats can catch Covid-19 from other cats. The question is: Can we? - STAT - May 15th, 2020
- Deficient Expression of DGCR8 in Human Testis is Related to Spermatoge | IJGM - Dove Medical Press - May 15th, 2020
- Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights - GlobeNewswire - May 15th, 2020
- Fulcrum Therapeutics, Inc. (FULC) Q1 2020 Earnings Call Transcript - The Motley Fool - May 15th, 2020
- Scientists concerned that coronavirus is adapting to humans - The Guardian - May 11th, 2020
- Coronavirus quickly spread around the world starting late last year, new genetic analysis shows - CNN - May 11th, 2020
- Your genes could determine whether the coronavirus puts you in the hospital and we're starting to unravel which ones matter - The Conversation US - May 11th, 2020
- Yes, COVID-19 is mutating, here's what you need to know - ABC News - May 11th, 2020
- Conservatives Are Not the Only Ones Who Ignore Facts and the Science - Merion West - May 11th, 2020
- Coronavirus in Scotland: Charity warns Covid will cause a spike in ME cases - as it calls for 'harmful' exercise treatment to be banned -... - May 11th, 2020
- Dr. Misaki Wayengera: The Man Behind Uganda's Covid 19 Test Kits - New Vision - May 11th, 2020
- Its In The Genes? Scientists Think Coronavirus Exploits Silent Hidden Mutations In The Body - International Business Times - May 11th, 2020
- From blood clots to 'Covid toe': Experts confounded by series of medical mysteries - The Straits Times - May 11th, 2020
- MET 2020 Slot booking to commence on July 15, Examination dates available at manipal.edu - Jagran Josh - May 11th, 2020
- Vitagene Launches The First FDA Authorized Saliva based Zero Contact COVID-19 At Home Test - Business Wire - May 10th, 2020
- Genetics in focus after coronavirus deaths of siblings and twins - The Guardian - May 10th, 2020
- 'An anvil on my chest': What it's like to have COVID-19 - LancasterOnline - May 10th, 2020
- Coronavirus may have spread to humans as early as October 2019 - study - The Jerusalem Post - May 10th, 2020
- Team reveals genomic history of ancient civilizations in the Andes - UC Santa Cruz - May 10th, 2020
- Regeneron Reports First Quarter 2020 Financial and Operating Results - BioSpace - May 10th, 2020
- Scientists at Ben-Gurion University of the Negev Develop Anti-Coronavirus Surface Coating Based on Nanomate... - The Auto Channel - May 10th, 2020
- COVID-19 and food security - Fitzwilliam College, University of Cambridge - May 10th, 2020
- Val Sheffield elected to the American Academy of Arts and Sciences - Iowa Now - May 1st, 2020
- DNA gives clues into risk of developing Alzheimer's disease and other dementias - Alabama NewsCenter - May 1st, 2020
- Rare Gene Discovered That Nearly Doubles Risk of Developing a Neurodegenerative Disease - Clinical OMICs News - May 1st, 2020
- Progress in understanding the genetic basis of mental health - SFARI News - May 1st, 2020
- Coronavirus was widespread in UK at very start of pandemic, says genetics expert - Sky News - May 1st, 2020
- This is how you do the genetics heritage filter on Instagram that everyone's doing - The Tab - May 1st, 2020
- COVID-19 vaccine in Ireland could take a year and a half - IrishCentral - May 1st, 2020
- MRC scientists elected Fellows of the Royal Society - Cambridge Network - May 1st, 2020
- Parkinson's discovery implicates "second brain" in the gut - New Atlas - May 1st, 2020
- Humans: are we the most effective vector of disease? - BugBitten - BMC Blogs Network - May 1st, 2020
- Could genetics explain why some COVID-19 patients fare worse than others? - Live Science - April 27th, 2020
- Human Genetics Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald - April 27th, 2020
- American Academy of Arts & Sciences Elects UVM's Wallace to Its Membership - UVM News - April 27th, 2020
- The PBS documentary The Gene showcases genetics promise and pitfalls - Science News - April 9th, 2020
- Few clinical trials are done in Africa: COVID-19 shows why this urgently needs to change - The Conversation Africa - April 9th, 2020
- UCLA web app will enlist publics help in slowing the spread of COVID-19 - Newswise - April 9th, 2020
- Why does the new coronavirus kill some people and barely affect others? - Wilkes-Barre Citizens Voice - April 9th, 2020
- COVID-19: Few Clinical Trials are Done in Africa. This Needs to Change ASAP. - The Wire - April 9th, 2020
- 'Behavioral suppression' needed to decrease coronavirus infections in Japan: experts - The Mainichi - April 9th, 2020
- The secret call of the wild: how animals teach each other to survive - The Guardian - April 9th, 2020
- Yann Joly on the fight against genetic discrimination - McGill Reporter - April 2nd, 2020
- Science to the rescue? How modern genetics could help save the world from coronavirus - Genetic Literacy Project - April 2nd, 2020
- Oldest human genetic data gleaned from 1.8-million-year-old tooth Haaretz - News Collective - April 2nd, 2020
- Science to the rescue? How modern genetics could help save the world from coronavirus - Alliance for Science - Alliance for Science - April 2nd, 2020
- BHU department claims to have discovered new technology to test COVID-19 - Jagran Josh - April 2nd, 2020
- Stealth BioTherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights - BioSpace - April 2nd, 2020
- Researchers at U of T developing antibodies to 'neutralize' novel coronavirus before it invades cells - News@UofT - April 2nd, 2020
- What is coronavirus and Covid-19? An explainer - KTVZ - April 2nd, 2020